Compare PMEC & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PMEC | CALC |
|---|---|---|
| Founded | 1984 | 2011 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.6M | 19.1M |
| IPO Year | 2021 | 2020 |
| Metric | PMEC | CALC |
|---|---|---|
| Price | $0.63 | $1.97 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 84.1K | ★ 239.3K |
| Earning Date | 07-24-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.31 | $0.44 |
| 52 Week High | $2.44 | $7.20 |
| Indicator | PMEC | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 63.59 | 64.98 |
| Support Level | $0.51 | $0.53 |
| Resistance Level | $0.80 | $2.39 |
| Average True Range (ATR) | 0.07 | 0.19 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 68.75 | 16.59 |
Primech Holdings Ltd is a cleaning business. The Company operates in two segments: commercial cleaning services and robotics. The Company is an established technology-driven facilities services provider in the public and private sectors operating mainly in Singapore. The Company generates revenue from services, which include services for general cleaning and maintenance of public and private facilities; cleaning of kitchen facilities of healthcare facilities, hotels and restaurants; and the supply of ad hoc customer; and cleaning services to offices.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.